^
Association details:
| Biomarker: | EHBP1‐MET fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a novel EHBP1-MET fusion in an intrahepatic cholangiocarcinoma responding to crizotinib
Published date:
09/08/2020
Excerpt:
...we report a 41‐year‐old female ICC patient with EHBP1‐MET fusion and multiple intrahepatic metastases responding to crizotinib…A novel EHBP1‐MET fusion was identified and confirmed by Sanger sequencing...the patient started treatment with MET inhibitors crizotinib. Magnetic resonance imaging (MRI) scan demonstrated a partial response for 8 months.
DOI:
https://doi.org/10.1634/theoncologist.2020-0535
